EMA Application withdrawn: Riquent (abetimus) — La Jolla Limited

View source ↗

Summary

The EMA withdrew the application for Riquent (abetimus) by La Jolla Limited for lupus nephritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus with Lupus Nephritis

Drugs mentioned

• Riquent

Snippet

Status: Application withdrawn. Therapeutic area: Lupus Nephritis. MAH: La Jolla Limited. Decision date: 31/12/2009